Binance, the global blockchain company behind the world's largest cryptocurrency exchange by trading volume and users, today announced it is offering direct USD deposits and withdrawals for its users in over 70 countries. https://mma.prnewswire.com/media/2801578/image.jpg Through BPay Global-a Payments Service Provider licensed and regulated by the Central Bank of Bahrain, and part of the Binance Group-retail […]
Onco3R Therapeutics reports first pre-clinical data from its best-in-class precision oncology portfolio at the 2025 AACR-NCI-EORTC symposium GlobeNewswire October 22, 2025 Three posters to be presented featuring pre-clinical data of potential best-in-class FGFR3 selective inhibitor, SMARCA2 selective inhibitor, and P53 Y220C reactivator Candidates for FGFR3 and SMARCA2 programs identified: IND enabling studies anticipated in mid-2026
NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) — 17a-4's eDisclaimer and WebParser are being offered as a bundle from now through year end. This limited-time offer is designed to help firms enhance compliance, manage web content efficiently, and maximize their technology budgets as the calendar year draws to a close. 17a-4's eDisclaimer addresses the legal
Co-led by Forbion and Sofinnova Partners, along with founding investor Monograph Capital, and Weatherden Innovative lead program, ELV001, in-licensed by Elevara from Japan's Teijin Pharma with good tolerability and safety, plus early signs of efficacy in Phase 1b Disrupting the treatment paradigm for patients with incomplete response to Standard of Care (Methotrexate + Tumor Necrosis
Elevara Medicines Raises $70 Million Series A to Advance Phase 2 Rheumatoid Arthritis Trial and Expand Pipeline GlobeNewswire October 22, 2025 Co-led by Forbion and Sofinnova Partners, along with founding investor Monograph Capital, and Weatherden Innovative lead program, ELV001, in-licensed by Elevara from Japan's Teijin Pharma with good tolerability and safety, plus early signs of
17a-4 offers eDisclaimer and WebParser Bundle for End-of-Year Savings eDisclaimer is available with the usual end of year discounts and now WebParser can be included too. This new bundle helps clients streamline website and email disclaimer compliance. GlobeNewswire October 22, 2025 NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) — 17a-4's eDisclaimer and WebParser are being
Pet Cancer Therapeutics Market Size Worth USD 1,150.70 Million by 2034 According to Precedence Research, the global pet cancer therapeutics market size will grow from USD 493.01 million in 2025 to nearly USD 1,150.70 million by 2034, with an expected CAGR of 9.89% from 2025 to 2034. GlobeNewswire October 22, 2025 Ottawa, Oct. 22, 2025
LISCure BioSciences (“LISCure”) announced that its proprietary joint health probiotic, JointWorks®, has been officially approved by the Korean Ministry of Food and Drug Safety (MFDS) as Recognized Health Functional Ingredient. This approval marks a historic milestone – JointWorks® is the world's first probiotic clinically proven to support joint healthand remains the onlyprobiotic ingredient approved by
New methodology accelerates validation cycles and boosts dimensional stability in polyamide applications With industries under pressure to replace metals with lighter, more durable materials, All Around Polymer (All Around Compounding), known for its Ardlon® brand, today unveiled a data-driven nylon compounding framework that drastically shortens validation cycles. This methodology positions the company at the forefront
Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; “Renalys”) is pleased to announce the company is providing financial support for the Alport Syndrome Registry Study organized by the Japanese Society for Pediatric Nephrology (Head Office: Chiyoda-ku, Tokyo). The study is headed by Professor Kandai Nozu, Department of Pediatrics, Graduate School of Medicine, Kobe University. Renalys will provide